| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 129 | 2025 | 1089 | 18.950 |
Why?
|
| Carcinoma, Squamous Cell | 90 | 2024 | 1105 | 12.790 |
Why?
|
| Neoplasm Recurrence, Local | 49 | 2025 | 1469 | 5.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 60 | 2025 | 2642 | 5.280 |
Why?
|
| Antineoplastic Agents | 50 | 2024 | 2422 | 5.250 |
Why?
|
| Quinazolines | 28 | 2019 | 216 | 4.650 |
Why?
|
| Thyroid Neoplasms | 19 | 2024 | 443 | 4.130 |
Why?
|
| ErbB Receptors | 29 | 2021 | 513 | 3.920 |
Why?
|
| Protein Kinase Inhibitors | 27 | 2024 | 611 | 3.520 |
Why?
|
| Mouth Neoplasms | 17 | 2024 | 202 | 3.090 |
Why?
|
| Chemoradiotherapy | 23 | 2025 | 328 | 2.750 |
Why?
|
| Antibodies, Monoclonal, Humanized | 27 | 2024 | 1020 | 2.640 |
Why?
|
| Cetuximab | 16 | 2022 | 119 | 2.430 |
Why?
|
| Biomarkers, Tumor | 19 | 2025 | 1665 | 2.150 |
Why?
|
| Neoplasms | 29 | 2025 | 3250 | 2.140 |
Why?
|
| Papillomavirus Infections | 12 | 2023 | 301 | 1.860 |
Why?
|
| Humans | 234 | 2025 | 96127 | 1.840 |
Why?
|
| Oropharyngeal Neoplasms | 7 | 2023 | 149 | 1.660 |
Why?
|
| Disease-Free Survival | 36 | 2021 | 1195 | 1.660 |
Why?
|
| Immunotherapy | 14 | 2024 | 763 | 1.600 |
Why?
|
| B7-H1 Antigen | 11 | 2024 | 305 | 1.570 |
Why?
|
| Indazoles | 8 | 2015 | 61 | 1.540 |
Why?
|
| Aged | 100 | 2025 | 20964 | 1.510 |
Why?
|
| Imidazoles | 8 | 2015 | 145 | 1.480 |
Why?
|
| Methotrexate | 10 | 2019 | 249 | 1.480 |
Why?
|
| TOR Serine-Threonine Kinases | 11 | 2021 | 217 | 1.430 |
Why?
|
| Middle Aged | 100 | 2025 | 28363 | 1.340 |
Why?
|
| Sirolimus | 8 | 2018 | 177 | 1.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2024 | 1172 | 1.280 |
Why?
|
| Programmed Cell Death 1 Receptor | 10 | 2024 | 188 | 1.270 |
Why?
|
| Female | 123 | 2025 | 50063 | 1.260 |
Why?
|
| Treatment Outcome | 57 | 2025 | 9173 | 1.240 |
Why?
|
| Lung Neoplasms | 12 | 2024 | 2463 | 1.220 |
Why?
|
| Male | 114 | 2025 | 45870 | 1.180 |
Why?
|
| Indoles | 9 | 2016 | 317 | 1.170 |
Why?
|
| Anilides | 6 | 2016 | 46 | 1.160 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2020 | 226 | 1.140 |
Why?
|
| Neoplasm Metastasis | 23 | 2025 | 1103 | 1.140 |
Why?
|
| Pyridines | 8 | 2016 | 319 | 1.090 |
Why?
|
| Adult | 85 | 2025 | 28718 | 1.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 157 | 1.020 |
Why?
|
| Molecular Targeted Therapy | 12 | 2024 | 305 | 1.020 |
Why?
|
| Aged, 80 and over | 44 | 2021 | 7232 | 1.000 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2012 | 303 | 0.960 |
Why?
|
| Cisplatin | 10 | 2025 | 611 | 0.940 |
Why?
|
| Neoplasm Staging | 26 | 2019 | 2081 | 0.920 |
Why?
|
| Quality of Life | 13 | 2021 | 1816 | 0.890 |
Why?
|
| Papillomaviridae | 8 | 2024 | 180 | 0.830 |
Why?
|
| Combined Modality Therapy | 25 | 2020 | 1773 | 0.810 |
Why?
|
| Induction Chemotherapy | 11 | 2021 | 151 | 0.810 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2019 | 647 | 0.810 |
Why?
|
| Precancerous Conditions | 6 | 2024 | 206 | 0.800 |
Why?
|
| Everolimus | 4 | 2022 | 36 | 0.800 |
Why?
|
| Fluorocarbons | 1 | 2023 | 72 | 0.780 |
Why?
|
| Mutation | 20 | 2024 | 4374 | 0.760 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2020 | 81 | 0.750 |
Why?
|
| Iodine Radioisotopes | 6 | 2023 | 138 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2016 | 367 | 0.710 |
Why?
|
| Survival Analysis | 20 | 2020 | 1546 | 0.710 |
Why?
|
| Phenylurea Compounds | 6 | 2015 | 99 | 0.700 |
Why?
|
| Carcinoma, Papillary | 5 | 2016 | 161 | 0.700 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 625 | 0.700 |
Why?
|
| Cell Line, Tumor | 18 | 2021 | 2794 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 10 | 2021 | 1431 | 0.660 |
Why?
|
| Prognosis | 23 | 2023 | 4033 | 0.660 |
Why?
|
| Disease Management | 4 | 2021 | 360 | 0.660 |
Why?
|
| Laryngeal Neoplasms | 4 | 2013 | 89 | 0.620 |
Why?
|
| Nasopharyngeal Neoplasms | 3 | 2015 | 47 | 0.620 |
Why?
|
| Human papillomavirus 16 | 5 | 2023 | 45 | 0.610 |
Why?
|
| Signal Transduction | 18 | 2021 | 3586 | 0.610 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2023 | 407 | 0.600 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 170 | 0.600 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2023 | 299 | 0.580 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 359 | 0.570 |
Why?
|
| Clinical Trials as Topic | 11 | 2016 | 1178 | 0.570 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 886 | 0.570 |
Why?
|
| Benzazepines | 1 | 2018 | 65 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2015 | 80 | 0.550 |
Why?
|
| Survivors | 2 | 2016 | 204 | 0.550 |
Why?
|
| Quinolines | 2 | 2015 | 89 | 0.540 |
Why?
|
| Algorithms | 3 | 2025 | 2014 | 0.530 |
Why?
|
| Fluorouracil | 15 | 2014 | 555 | 0.530 |
Why?
|
| Patient Selection | 8 | 2021 | 709 | 0.520 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 294 | 0.510 |
Why?
|
| Tumor Microenvironment | 8 | 2024 | 568 | 0.510 |
Why?
|
| Research Design | 5 | 2014 | 631 | 0.510 |
Why?
|
| Survival Rate | 12 | 2016 | 1986 | 0.510 |
Why?
|
| Consensus | 2 | 2019 | 370 | 0.500 |
Why?
|
| Radiation-Sensitizing Agents | 3 | 2020 | 100 | 0.500 |
Why?
|
| Precision Medicine | 4 | 2021 | 451 | 0.500 |
Why?
|
| Mice, Nude | 9 | 2019 | 842 | 0.490 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2013 | 15 | 0.490 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2015 | 43 | 0.480 |
Why?
|
| Receptor, ErbB-2 | 6 | 2019 | 280 | 0.480 |
Why?
|
| Dasatinib | 1 | 2015 | 39 | 0.480 |
Why?
|
| Drug Administration Schedule | 8 | 2018 | 873 | 0.470 |
Why?
|
| Erlotinib Hydrochloride | 6 | 2016 | 90 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1096 | 0.450 |
Why?
|
| Aftercare | 1 | 2016 | 90 | 0.450 |
Why?
|
| Anticarcinogenic Agents | 2 | 2016 | 71 | 0.450 |
Why?
|
| Glutamates | 2 | 2012 | 90 | 0.450 |
Why?
|
| Administration, Oral | 10 | 2021 | 688 | 0.450 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 41 | 0.450 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 114 | 0.450 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2016 | 307 | 0.440 |
Why?
|
| Maximum Tolerated Dose | 10 | 2017 | 270 | 0.440 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 6 | 2023 | 63 | 0.430 |
Why?
|
| Guanine | 2 | 2012 | 207 | 0.430 |
Why?
|
| Benzimidazoles | 2 | 2012 | 112 | 0.420 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 355 | 0.420 |
Why?
|
| Pyrroles | 4 | 2015 | 172 | 0.410 |
Why?
|
| Palliative Care | 2 | 2015 | 273 | 0.410 |
Why?
|
| Radiodermatitis | 1 | 2013 | 10 | 0.410 |
Why?
|
| Mucositis | 1 | 2013 | 18 | 0.410 |
Why?
|
| Neoplasm Invasiveness | 4 | 2012 | 590 | 0.400 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 204 | 0.400 |
Why?
|
| Double-Blind Method | 8 | 2025 | 1791 | 0.400 |
Why?
|
| Adenocarcinoma | 4 | 2023 | 1215 | 0.400 |
Why?
|
| Food-Drug Interactions | 1 | 2013 | 19 | 0.390 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2021 | 76 | 0.390 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2017 | 244 | 0.390 |
Why?
|
| Hot Temperature | 1 | 2013 | 217 | 0.380 |
Why?
|
| Information Dissemination | 1 | 2013 | 126 | 0.380 |
Why?
|
| Publishing | 1 | 2013 | 94 | 0.380 |
Why?
|
| Medical Oncology | 4 | 2019 | 408 | 0.370 |
Why?
|
| Health Status | 1 | 2014 | 386 | 0.370 |
Why?
|
| Hydroxyurea | 12 | 2014 | 239 | 0.370 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 20 | 0.360 |
Why?
|
| Clinical Trials, Phase III as Topic | 6 | 2022 | 178 | 0.360 |
Why?
|
| Surveys and Questionnaires | 6 | 2018 | 2860 | 0.360 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 39 | 0.360 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 171 | 0.350 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2012 | 57 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2021 | 1973 | 0.350 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2008 | 224 | 0.340 |
Why?
|
| Sulfonamides | 5 | 2016 | 338 | 0.340 |
Why?
|
| Bevacizumab | 6 | 2011 | 276 | 0.340 |
Why?
|
| Mice | 15 | 2022 | 12562 | 0.330 |
Why?
|
| Leukoplakia, Oral | 3 | 2024 | 12 | 0.330 |
Why?
|
| Animals | 22 | 2022 | 28945 | 0.330 |
Why?
|
| Thyroid Gland | 1 | 2012 | 281 | 0.330 |
Why?
|
| Radiotherapy Dosage | 10 | 2016 | 482 | 0.330 |
Why?
|
| Patient Care Team | 1 | 2013 | 307 | 0.320 |
Why?
|
| Disease Progression | 10 | 2020 | 1568 | 0.320 |
Why?
|
| Cohort Studies | 8 | 2025 | 3107 | 0.320 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2011 | 159 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 107 | 0.310 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2022 | 172 | 0.310 |
Why?
|
| Mouth Mucosa | 3 | 2021 | 71 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2016 | 23 | 0.310 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 147 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 935 | 0.300 |
Why?
|
| Immunohistochemistry | 7 | 2020 | 1829 | 0.300 |
Why?
|
| Diarrhea | 4 | 2014 | 181 | 0.300 |
Why?
|
| Protein Kinase C-alpha | 1 | 2009 | 29 | 0.290 |
Why?
|
| Metformin | 2 | 2021 | 126 | 0.290 |
Why?
|
| Skin | 1 | 2012 | 605 | 0.290 |
Why?
|
| Biopsy | 4 | 2021 | 1220 | 0.290 |
Why?
|
| Thalidomide | 3 | 2015 | 56 | 0.280 |
Why?
|
| Radiation Tolerance | 4 | 2016 | 176 | 0.280 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2016 | 162 | 0.280 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 354 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 535 | 0.280 |
Why?
|
| ras Proteins | 3 | 2016 | 134 | 0.280 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 456 | 0.280 |
Why?
|
| United States | 15 | 2020 | 7767 | 0.270 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 810 | 0.270 |
Why?
|
| Esophageal Neoplasms | 3 | 2017 | 346 | 0.270 |
Why?
|
| Radiotherapy | 6 | 2020 | 328 | 0.270 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 1268 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2021 | 518 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 444 | 0.260 |
Why?
|
| Retrospective Studies | 17 | 2023 | 10286 | 0.250 |
Why?
|
| Retreatment | 5 | 2015 | 106 | 0.250 |
Why?
|
| Protein Kinases | 1 | 2008 | 216 | 0.250 |
Why?
|
| Niacinamide | 5 | 2014 | 102 | 0.250 |
Why?
|
| Triazines | 1 | 2007 | 55 | 0.250 |
Why?
|
| DNA, Neoplasm | 3 | 2017 | 272 | 0.250 |
Why?
|
| Eating | 1 | 2007 | 165 | 0.250 |
Why?
|
| Young Adult | 11 | 2019 | 7025 | 0.250 |
Why?
|
| Time Factors | 9 | 2020 | 5585 | 0.240 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 116 | 0.240 |
Why?
|
| Apoptosis | 5 | 2023 | 1763 | 0.240 |
Why?
|
| Deoxycytidine | 2 | 2011 | 215 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 771 | 0.240 |
Why?
|
| Immunotoxins | 1 | 2005 | 16 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2015 | 81 | 0.240 |
Why?
|
| Genomics | 4 | 2015 | 855 | 0.240 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 67 | 0.230 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2018 | 46 | 0.230 |
Why?
|
| Tongue Neoplasms | 3 | 2017 | 51 | 0.230 |
Why?
|
| Tumor Escape | 3 | 2020 | 53 | 0.230 |
Why?
|
| Protein Kinase C | 1 | 2006 | 267 | 0.230 |
Why?
|
| Immunologic Factors | 3 | 2021 | 179 | 0.230 |
Why?
|
| Viral Vaccines | 2 | 2003 | 48 | 0.230 |
Why?
|
| Drug Approval | 2 | 2019 | 69 | 0.230 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 147 | 0.220 |
Why?
|
| Fatigue | 3 | 2016 | 185 | 0.220 |
Why?
|
| Veterans | 2 | 2023 | 100 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 180 | 0.220 |
Why?
|
| Vinblastine | 2 | 2002 | 100 | 0.220 |
Why?
|
| Risk Factors | 11 | 2019 | 5960 | 0.220 |
Why?
|
| Genes, p53 | 2 | 2015 | 109 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1316 | 0.220 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2015 | 285 | 0.210 |
Why?
|
| Evidence-Based Dentistry | 3 | 2017 | 10 | 0.210 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 229 | 0.210 |
Why?
|
| Clinical Protocols | 2 | 2014 | 162 | 0.210 |
Why?
|
| MicroRNAs | 1 | 2009 | 592 | 0.210 |
Why?
|
| Piperazines | 3 | 2017 | 296 | 0.210 |
Why?
|
| Receptor, ErbB-3 | 2 | 2021 | 19 | 0.210 |
Why?
|
| Aminobenzoates | 2 | 2022 | 7 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1351 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2021 | 1761 | 0.200 |
Why?
|
| Fluorine | 1 | 2023 | 17 | 0.200 |
Why?
|
| Mitochondria | 1 | 2007 | 623 | 0.200 |
Why?
|
| Smoking | 5 | 2014 | 653 | 0.200 |
Why?
|
| Deglutition | 3 | 2013 | 85 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 208 | 0.190 |
Why?
|
| Platinum | 5 | 2016 | 67 | 0.190 |
Why?
|
| Alcohol Drinking | 4 | 2013 | 287 | 0.190 |
Why?
|
| Biomarkers | 6 | 2021 | 1933 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2023 | 938 | 0.190 |
Why?
|
| Immunomodulation | 2 | 2021 | 64 | 0.190 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 3927 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 3 | 2011 | 247 | 0.190 |
Why?
|
| Oligopeptides | 2 | 2022 | 195 | 0.190 |
Why?
|
| Cell Cycle | 3 | 2010 | 518 | 0.180 |
Why?
|
| Carboplatin | 6 | 2019 | 331 | 0.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 325 | 0.180 |
Why?
|
| Drug Monitoring | 2 | 2019 | 120 | 0.180 |
Why?
|
| Pain Management | 2 | 2015 | 179 | 0.180 |
Why?
|
| Adenoviridae | 2 | 2003 | 342 | 0.180 |
Why?
|
| Pemetrexed | 2 | 2012 | 76 | 0.180 |
Why?
|
| Benzenesulfonates | 3 | 2011 | 50 | 0.170 |
Why?
|
| Immunoconjugates | 1 | 2022 | 131 | 0.170 |
Why?
|
| Gene Deletion | 2 | 2014 | 358 | 0.170 |
Why?
|
| Deglutition Disorders | 2 | 2016 | 126 | 0.170 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 45 | 0.170 |
Why?
|
| Muscle Neoplasms | 1 | 2001 | 17 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2018 | 854 | 0.170 |
Why?
|
| Carcinoma | 3 | 2015 | 449 | 0.170 |
Why?
|
| Genetic Therapy | 2 | 2012 | 382 | 0.170 |
Why?
|
| Taxoids | 2 | 2014 | 131 | 0.170 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 381 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2016 | 238 | 0.170 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 19 | 0.170 |
Why?
|
| Immune System | 1 | 2021 | 103 | 0.170 |
Why?
|
| Vaccines, Subunit | 1 | 2020 | 55 | 0.170 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2020 | 6 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 43 | 0.160 |
Why?
|
| Blood Pressure | 3 | 2014 | 929 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2019 | 188 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2022 | 4671 | 0.160 |
Why?
|
| Heterografts | 2 | 2017 | 117 | 0.160 |
Why?
|
| Paclitaxel | 6 | 2012 | 498 | 0.160 |
Why?
|
| Rimantadine | 1 | 2019 | 9 | 0.160 |
Why?
|
| Doxorubicin | 1 | 2001 | 304 | 0.160 |
Why?
|
| Quinolones | 1 | 2020 | 57 | 0.160 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2019 | 33 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2014 | 156 | 0.160 |
Why?
|
| Nomograms | 1 | 2019 | 35 | 0.150 |
Why?
|
| Age Factors | 3 | 2019 | 1963 | 0.150 |
Why?
|
| Melanoma | 1 | 2024 | 497 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 186 | 0.150 |
Why?
|
| Models, Immunological | 1 | 2019 | 85 | 0.150 |
Why?
|
| Genotype | 2 | 2015 | 1882 | 0.150 |
Why?
|
| Drug Synergism | 3 | 2018 | 318 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 145 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 855 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2013 | 40 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2015 | 54 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 501 | 0.140 |
Why?
|
| Biological Products | 1 | 2020 | 179 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2016 | 2480 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 404 | 0.140 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2017 | 24 | 0.140 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2017 | 15 | 0.140 |
Why?
|
| Cell Growth Processes | 2 | 2009 | 85 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 481 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 66 | 0.130 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2009 | 50 | 0.130 |
Why?
|
| Confidence Intervals | 4 | 2019 | 220 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 458 | 0.130 |
Why?
|
| Gene Expression | 2 | 2014 | 1322 | 0.130 |
Why?
|
| Immune Tolerance | 2 | 2019 | 385 | 0.130 |
Why?
|
| Models, Biological | 3 | 2014 | 1815 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2018 | 218 | 0.130 |
Why?
|
| Base Sequence | 3 | 2014 | 2344 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 382 | 0.130 |
Why?
|
| Mice, Inbred C3H | 1 | 2017 | 372 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2016 | 28 | 0.130 |
Why?
|
| Robotic Surgical Procedures | 1 | 2023 | 367 | 0.130 |
Why?
|
| Macrophages | 2 | 2017 | 626 | 0.130 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2016 | 4 | 0.130 |
Why?
|
| Proto-Oncogenes | 1 | 2016 | 61 | 0.130 |
Why?
|
| Pyrazines | 2 | 2022 | 94 | 0.130 |
Why?
|
| Peptides | 2 | 2022 | 672 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1807 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2781 | 0.120 |
Why?
|
| Accessory Nerve Diseases | 1 | 2016 | 1 | 0.120 |
Why?
|
| Dental Caries | 1 | 2016 | 4 | 0.120 |
Why?
|
| Trismus | 1 | 2016 | 6 | 0.120 |
Why?
|
| Xerostomia | 1 | 2016 | 10 | 0.120 |
Why?
|
| Voice Disorders | 1 | 2016 | 7 | 0.120 |
Why?
|
| Respiratory Aspiration | 1 | 2016 | 6 | 0.120 |
Why?
|
| Taste Disorders | 1 | 2016 | 10 | 0.120 |
Why?
|
| Periodontitis | 1 | 2016 | 8 | 0.120 |
Why?
|
| American Cancer Society | 1 | 2016 | 13 | 0.120 |
Why?
|
| Dental Care | 1 | 2016 | 12 | 0.120 |
Why?
|
| Benzamides | 2 | 2022 | 248 | 0.120 |
Why?
|
| Stomatitis | 1 | 2016 | 30 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2012 | 366 | 0.120 |
Why?
|
| Osteonecrosis | 1 | 2016 | 21 | 0.120 |
Why?
|
| Vestibular Neuronitis | 1 | 2016 | 5 | 0.120 |
Why?
|
| Neck Muscles | 1 | 2016 | 19 | 0.120 |
Why?
|
| Dystonia | 1 | 2016 | 31 | 0.120 |
Why?
|
| Bursitis | 1 | 2016 | 14 | 0.120 |
Why?
|
| Peptide Hormones | 1 | 2016 | 30 | 0.120 |
Why?
|
| Mass Screening | 2 | 2012 | 710 | 0.120 |
Why?
|
| Circulating Tumor DNA | 1 | 2017 | 75 | 0.120 |
Why?
|
| Pyrimidinones | 1 | 2016 | 44 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 684 | 0.120 |
Why?
|
| Pyridones | 1 | 2016 | 68 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 111 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2019 | 644 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 91 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2015 | 74 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 30 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1010 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 84 | 0.110 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2016 | 106 | 0.110 |
Why?
|
| Pneumonia, Aspiration | 1 | 2014 | 21 | 0.110 |
Why?
|
| Receptors, IgG | 1 | 2015 | 68 | 0.110 |
Why?
|
| Lymphedema | 1 | 2016 | 84 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 128 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2018 | 1157 | 0.110 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 121 | 0.110 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2014 | 6 | 0.110 |
Why?
|
| Health Promotion | 1 | 2016 | 176 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 310 | 0.110 |
Why?
|
| Proteomics | 2 | 2022 | 269 | 0.110 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2014 | 12 | 0.110 |
Why?
|
| Drug Interactions | 3 | 2011 | 245 | 0.110 |
Why?
|
| Sequestosome-1 Protein | 1 | 2014 | 23 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 83 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2016 | 477 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 436 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2014 | 51 | 0.100 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 44 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 132 | 0.100 |
Why?
|
| Transcription Factors | 2 | 2016 | 1730 | 0.100 |
Why?
|
| Licensure | 1 | 2013 | 7 | 0.100 |
Why?
|
| DNA Primers | 2 | 2014 | 548 | 0.100 |
Why?
|
| Population Groups | 1 | 2013 | 42 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2019 | 599 | 0.100 |
Why?
|
| Peer Review | 1 | 2013 | 24 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2013 | 82 | 0.100 |
Why?
|
| Focus Groups | 1 | 2014 | 189 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 399 | 0.100 |
Why?
|
| Aminolevulinic Acid | 1 | 2013 | 23 | 0.100 |
Why?
|
| Anxiety | 1 | 2016 | 339 | 0.100 |
Why?
|
| Erythropoiesis | 1 | 2013 | 53 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2009 | 311 | 0.100 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 52 | 0.100 |
Why?
|
| Economics, Pharmaceutical | 1 | 2013 | 10 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 668 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 3147 | 0.100 |
Why?
|
| Area Under Curve | 5 | 2014 | 340 | 0.100 |
Why?
|
| Hypothyroidism | 1 | 2016 | 276 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 276 | 0.100 |
Why?
|
| Italy | 1 | 2013 | 112 | 0.100 |
Why?
|
| Magnetics | 1 | 2013 | 43 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2014 | 376 | 0.100 |
Why?
|
| Micelles | 1 | 2013 | 53 | 0.100 |
Why?
|
| Gastrostomy | 1 | 2013 | 69 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2016 | 345 | 0.100 |
Why?
|
| Citrus paradisi | 1 | 2012 | 5 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3651 | 0.100 |
Why?
|
| United Kingdom | 1 | 2013 | 192 | 0.100 |
Why?
|
| Photochemotherapy | 1 | 2013 | 101 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2014 | 1534 | 0.100 |
Why?
|
| Ketoconazole | 1 | 2012 | 24 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2012 | 32 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2014 | 361 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2014 | 386 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2009 | 192 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 396 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2012 | 28 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2013 | 106 | 0.090 |
Why?
|
| DNA Repair | 1 | 2014 | 376 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 232 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 92 | 0.090 |
Why?
|
| Autophagy | 1 | 2014 | 177 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2011 | 1069 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2013 | 311 | 0.090 |
Why?
|
| Radiography | 2 | 2014 | 826 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 567 | 0.090 |
Why?
|
| Depression | 1 | 2016 | 560 | 0.090 |
Why?
|
| Bibenzyls | 1 | 2011 | 2 | 0.090 |
Why?
|
| Exanthema | 1 | 2012 | 41 | 0.090 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 16 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2011 | 27 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2008 | 315 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2019 | 819 | 0.090 |
Why?
|
| Valproic Acid | 1 | 2011 | 25 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 465 | 0.090 |
Why?
|
| Depsipeptides | 1 | 2011 | 32 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2012 | 181 | 0.090 |
Why?
|
| Tracheotomy | 1 | 2011 | 18 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 52 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 55 | 0.090 |
Why?
|
| Carbazoles | 1 | 2011 | 31 | 0.090 |
Why?
|
| Bortezomib | 1 | 2011 | 82 | 0.090 |
Why?
|
| Psoriasis | 1 | 2014 | 254 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 127 | 0.090 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 124 | 0.090 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 46 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2013 | 197 | 0.080 |
Why?
|
| Oligonucleotides | 1 | 2011 | 92 | 0.080 |
Why?
|
| Drug Eruptions | 1 | 2011 | 35 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2011 | 93 | 0.080 |
Why?
|
| Cyclin D1 | 1 | 2010 | 85 | 0.080 |
Why?
|
| Camptothecin | 1 | 2011 | 204 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 413 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 107 | 0.080 |
Why?
|
| Probability | 5 | 2009 | 365 | 0.080 |
Why?
|
| Sexual Behavior | 1 | 2013 | 334 | 0.080 |
Why?
|
| Speech | 1 | 2010 | 91 | 0.080 |
Why?
|
| Piperidines | 1 | 2011 | 171 | 0.080 |
Why?
|
| Airway Obstruction | 1 | 2011 | 117 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 547 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2010 | 412 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 2 | 2021 | 145 | 0.080 |
Why?
|
| Cell Line | 2 | 2011 | 2533 | 0.080 |
Why?
|
| Thermography | 1 | 2009 | 12 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1054 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 377 | 0.080 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 52 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 206 | 0.070 |
Why?
|
| Cyclin E | 1 | 2009 | 28 | 0.070 |
Why?
|
| Endpoint Determination | 1 | 2009 | 59 | 0.070 |
Why?
|
| Demography | 1 | 2009 | 189 | 0.070 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 49 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2013 | 441 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 386 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2018 | 1134 | 0.070 |
Why?
|
| Cell Survival | 1 | 2011 | 1032 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2092 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 701 | 0.070 |
Why?
|
| Adolescent | 6 | 2019 | 9896 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2011 | 316 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2008 | 910 | 0.070 |
Why?
|
| Research | 1 | 2009 | 265 | 0.070 |
Why?
|
| Economics, Medical | 1 | 2007 | 6 | 0.070 |
Why?
|
| Drug Packaging | 1 | 2007 | 7 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 3041 | 0.070 |
Why?
|
| Drug Labeling | 1 | 2007 | 42 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 829 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 367 | 0.060 |
Why?
|
| DNA | 1 | 2012 | 1332 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2007 | 197 | 0.060 |
Why?
|
| Benzophenanthridines | 1 | 2006 | 23 | 0.060 |
Why?
|
| Butadienes | 1 | 2006 | 34 | 0.060 |
Why?
|
| Phenanthridines | 1 | 2006 | 24 | 0.060 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 27 | 0.060 |
Why?
|
| Cell Dedifferentiation | 1 | 2006 | 10 | 0.060 |
Why?
|
| Remission Induction | 3 | 2016 | 769 | 0.060 |
Why?
|
| Alkaloids | 1 | 2006 | 47 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 259 | 0.060 |
Why?
|
| Phenotype | 1 | 2012 | 2579 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 157 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 558 | 0.060 |
Why?
|
| American Dental Association | 2 | 2017 | 9 | 0.060 |
Why?
|
| Keratinocytes | 1 | 2006 | 146 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2006 | 418 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 40 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2006 | 692 | 0.060 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 484 | 0.060 |
Why?
|
| Proteasome Inhibitors | 1 | 2004 | 54 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2004 | 42 | 0.050 |
Why?
|
| SEER Program | 2 | 2016 | 235 | 0.050 |
Why?
|
| Incidence | 3 | 2017 | 1715 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2003 | 5 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 466 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 589 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 191 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2004 | 172 | 0.050 |
Why?
|
| Forecasting | 2 | 2019 | 317 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 68 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 2 | 2015 | 26 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 31 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2016 | 14 | 0.050 |
Why?
|
| Interferons | 1 | 2023 | 130 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2018 | 713 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 2551 | 0.050 |
Why?
|
| Infant | 2 | 2023 | 3363 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 423 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 1 | 2022 | 86 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2002 | 20 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2015 | 143 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2015 | 105 | 0.050 |
Why?
|
| Medicare | 2 | 2016 | 458 | 0.040 |
Why?
|
| Inflammation | 2 | 2019 | 1068 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 89 | 0.040 |
Why?
|
| Illinois | 1 | 2003 | 531 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2002 | 215 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 162 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 1133 | 0.040 |
Why?
|
| Cytodiagnosis | 2 | 2012 | 47 | 0.040 |
Why?
|
| Germany | 1 | 2021 | 80 | 0.040 |
Why?
|
| Lymphopoiesis | 1 | 2021 | 48 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 436 | 0.040 |
Why?
|
| Placebos | 1 | 2021 | 213 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2021 | 181 | 0.040 |
Why?
|
| Urothelium | 1 | 2001 | 69 | 0.040 |
Why?
|
| Standard of Care | 1 | 2021 | 70 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 750 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 20 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2020 | 100 | 0.040 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.040 |
Why?
|
| Models, Economic | 1 | 2020 | 62 | 0.040 |
Why?
|
| Thinness | 1 | 2019 | 45 | 0.040 |
Why?
|
| Child | 3 | 2018 | 7626 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 144 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 57 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2019 | 30 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 157 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 157 | 0.040 |
Why?
|
| Smokers | 1 | 2019 | 55 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 173 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 377 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2022 | 710 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 79 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 286 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 198 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2018 | 32 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2019 | 229 | 0.040 |
Why?
|
| Laryngectomy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 285 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 296 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 527 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 209 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 45 | 0.030 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 245 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2022 | 541 | 0.030 |
Why?
|
| Mouth | 1 | 2017 | 49 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 116 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 105 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 706 | 0.030 |
Why?
|
| Reference Values | 2 | 2009 | 675 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2019 | 192 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 212 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.030 |
Why?
|
| Neck Dissection | 2 | 2008 | 68 | 0.030 |
Why?
|
| Acrylamides | 1 | 2017 | 35 | 0.030 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2016 | 11 | 0.030 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2016 | 7 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 901 | 0.030 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 63 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 323 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 72 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 120 | 0.030 |
Why?
|
| Decision Making | 1 | 2002 | 694 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 298 | 0.030 |
Why?
|
| Financing, Government | 1 | 2016 | 26 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 86 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1011 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 404 | 0.030 |
Why?
|
| Snake Venoms | 1 | 2015 | 9 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 454 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 214 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2015 | 13 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 385 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 278 | 0.030 |
Why?
|
| Cell Division | 1 | 2016 | 705 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 514 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 89 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 74 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 297 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 85 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 53 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 1192 | 0.030 |
Why?
|
| Anorexia | 1 | 2014 | 28 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 119 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 280 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1349 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 22 | 0.030 |
Why?
|
| Calcitonin | 1 | 2013 | 40 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2013 | 41 | 0.030 |
Why?
|
| Leg | 1 | 2014 | 143 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2016 | 684 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 15 | 0.030 |
Why?
|
| Receptor, ErbB-4 | 1 | 2013 | 5 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 469 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 301 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2040 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2013 | 91 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2014 | 521 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2014 | 161 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 53 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 259 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 99 | 0.020 |
Why?
|
| Tolonium Chloride | 1 | 2012 | 5 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 126 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2012 | 65 | 0.020 |
Why?
|
| Saliva | 1 | 2013 | 128 | 0.020 |
Why?
|
| Vomiting | 1 | 2014 | 201 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 286 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2012 | 43 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 554 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 328 | 0.020 |
Why?
|
| Supraglottitis | 1 | 2011 | 3 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2943 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 39 | 0.020 |
Why?
|
| Physical Examination | 1 | 2012 | 154 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 204 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 43 | 0.020 |
Why?
|
| Light | 1 | 2012 | 297 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2011 | 236 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 397 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2010 | 29 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 318 | 0.020 |
Why?
|
| Mercury Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cadmium Compounds | 1 | 2009 | 2 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 797 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3490 | 0.020 |
Why?
|
| Laboratories | 1 | 2009 | 48 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2010 | 153 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 943 | 0.020 |
Why?
|
| Nitrogen | 1 | 2009 | 79 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 15 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2009 | 212 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2014 | 2614 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2008 | 66 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2008 | 84 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2008 | 165 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 81 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 898 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 427 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 89 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 2008 | 104 | 0.020 |
Why?
|
| Temperature | 1 | 2009 | 426 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2009 | 201 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2010 | 286 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 909 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 750 | 0.020 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 94 | 0.020 |
Why?
|
| Organ Preservation | 1 | 2008 | 130 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 3974 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2494 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 798 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 815 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 126 | 0.020 |
Why?
|
| Phospholipids | 1 | 2006 | 113 | 0.020 |
Why?
|
| Genome, Human | 1 | 2010 | 824 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 46 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 100 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2092 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2003 | 86 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1276 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 313 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1763 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1981 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 4154 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1958 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 986 | 0.010 |
Why?
|